Investment Summary

Bay City Capital Invests In Epizyme

On May 31, 2013, venture capital firm Bay City Capital invested in life science company Epizyme from Bay City Capital

Investment Highlights
  • This is Bay City Capital’s 49th transaction in the Life Science sector.
  • This is Bay City Capital’s 65th transaction in the United States.
  • This is Bay City Capital’s 8th transaction in Massachusetts.
Investment Fate
  • Epizyme was sold to a consortium of buyers in 2022 for 247M USD.

Investment Summary

Date 2013-05-31
Target Epizyme
Sector Life Science
Investor(s) Bay City Capital
Sellers(s) Bay City Capital
Deal Type PIPE

Target

Epizyme

Cambridge, Massachusetts, United States
Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme was founded in 2007 and is based in Cambridge, Massachusetts.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Bay City Capital

San Rafael, California, United States

Investor Investor Investor Investor Investor


Category Venture Capital Firm
Founded 1997
PE ASSETS 1.3B USD
Size Large
Type Sector Focused
DESCRIPTION

Bay City Capital LLC was established in 1997 as an equal partnership between The Craves Group and certain Pritzker family business interests for the purpose of managing investment funds in the life sciences industry. Bay City looks for opportunities at all stages of development in biopharmaceuticals, drug discovery, medical devices and diagnostics. Bay City Capital is based in San Francisco, California.


DEAL STATS #
Overall 68 of 75
Sector (Life Science) 49 of 54
Type (PIPE) 3 of 4
State (Massachusetts) 8 of 10
Country (United States) 65 of 72
Year (2013) 4 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-05-22 Interleukin Genetics

Waltham, Massachusetts, United States

Interleukin Genetics, Inc. is a genetics-based personalized health company that develops genetic tests for use in the emerging personalized health market. Our vision is to build a leading personalized health and wellness company.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-06-14 Conatus Pharmaceuticals

San Diego, California, United States

Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus Pharmaceuticals was founded in 2005 and is based in San Diego, California.

Sell -

Seller(S) 1

SELLER

Bay City Capital

San Rafael, California, United States

Investor Investor Investor Investor Investor


Category Venture Capital Firm
Founded 1997
PE ASSETS 1.3B USD
Size Large
Type Sector Focused
DESCRIPTION

Bay City Capital LLC was established in 1997 as an equal partnership between The Craves Group and certain Pritzker family business interests for the purpose of managing investment funds in the life sciences industry. Bay City looks for opportunities at all stages of development in biopharmaceuticals, drug discovery, medical devices and diagnostics. Bay City Capital is based in San Francisco, California.


DEAL STATS #
Overall 44 of 62
Sector (Life Science) 30 of 45
Type (PIPE) 1 of 1
State (Massachusetts) 4 of 8
Country (United States) 42 of 59
Year (2013) 4 of 8
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-05-22 Interleukin Genetics

Waltham, Massachusetts, United States

Interleukin Genetics, Inc. is a genetics-based personalized health company that develops genetic tests for use in the emerging personalized health market. Our vision is to build a leading personalized health and wellness company.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-06-14 Conatus Pharmaceuticals

San Diego, California, United States

Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus Pharmaceuticals was founded in 2005 and is based in San Diego, California.

Sell -